PARTNER ORGANISATIONS

 Our Track Record

Since starting operations in 2009, SingHealth IMU has attracted more than 40 clinical trials, of which 60 per cent are industry-sponsored. To date, 20 clinical trials have been completed. SingHealth IMU’s ongoing trials are in the areas of:

  • Oncology 
  • Healthy volunteer studies
  • Haematology 
  • Lymphoma
  • Gastroenterology
  • Cardiology
  • Nephrology 

Ongoing Projects 

 IMPACT programme in oncology (individualised molecular profiling for allocation to clinical trials)
 Allergen & immunology research initiative
 Infectious diseases (dengue, influenza)
 Clinical pharmacology & pharmacogenetics programme
 Chronobiology sleep and circadian rhythm studies

Collaboration with Duke University

SingHealth IMU, Duke University’s Clinical Resarch Unit (Carolina, USA) and Medanta IMU (India) have signed a memorandum of understanding to facilitate appropriate multi-site studies at the three institutions.

Project that has been initiated since its launch include:
  • Microarray signatures to aspirin response study

Collaboration with Industry

SingHealth IMU has collaborative agreements with most major pharmaceutical companies and CROs, including:
  • Covance
  • Parexel
  • Quintiles
  • MSD 
  • GlaxoSmithKline (GSK)
  • Novartis OTM
  • Pharmanet
  • PPD
  • Servier
  • Pfizer  
  • Esai
  • Takeda/Millennium
  • Bayer
  • Boehringer Ingelheim
  • Sanofi
  • Fibrogen
  • AstraZeneca

Site audits

SingHealth IMU has been audited by the Health Sciences Authority of Singapore and by Pharmanet and is approved as a full clinical trial site.